Janus Henderson Group PLC Sage Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

$187 Billion
Q3 2024

A detailed history of Janus Henderson Group PLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 25,893 shares of SAGE stock, worth $148,366. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,893

Previous 25,893 -0.0%

Holding current value

$148,366

Previous $281,000 33.81%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$10.58 - $17.9 $2,814 - $4,761	-266 Reduced 1.02%	25,893 $281,000
Q4 2023 Feb 14, 2024	SELL	$17.1 - $22.26 $684 - $890	-40 Reduced 0.15%	26,159 $566,000
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $67 - $195	4 Added 0.02%	26,199 $539,000
Q2 2023 Aug 14, 2023	SELL	$40.65 - $59.54 $16 Million - $23.4 Million	-392,551 Reduced 93.74%	26,195 $1.23 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $46.57 $7.47 Million - $9.34 Million	-200,544 Reduced 32.38%	418,746 $17.6 Million
Q4 2022 Feb 14, 2023	SELL	$32.2 - $43.61 $3.61 Million - $4.89 Million	-112,133 Reduced 15.33%	619,290 $23.6 Million
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $1.15 Million - $1.54 Million	-35,626 Reduced 4.64%	731,423 $28.6 Million
Q2 2022 Aug 15, 2022	SELL	$27.52 - $37.99 $7.24 Million - $9.99 Million	-262,904 Reduced 25.53%	767,049 $24.8 Million
Q1 2022 May 16, 2022	BUY	$30.71 - $45.71 $1.69 Million - $2.51 Million	54,971 Added 5.64%	1,029,953 $34.1 Million
Q4 2021 Feb 14, 2022	SELL	$37.06 - $47.11 $2.82 Million - $3.58 Million	-76,011 Reduced 7.23%	974,982 $41.5 Million
Q3 2021 Nov 16, 2021	SELL	$40.26 - $57.37 $24.5 Million - $35 Million	-609,460 Reduced 36.7%	1,050,993 $46.6 Million
Q2 2021 Aug 16, 2021	SELL	$54.88 - $79.29 $11.7 Million - $16.9 Million	-212,929 Reduced 11.37%	1,660,453 $94.3 Million
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $7.45 Million - $10.2 Million	-105,429 Reduced 5.33%	1,873,382 $140 Million
Q4 2020 Feb 16, 2021	BUY	$58.41 - $89.06 $21 Million - $32 Million	359,110 Added 22.17%	1,978,811 $171 Million
Q3 2020 Nov 16, 2020	BUY	$41.13 - $62.45 $6.58 Million - $9.99 Million	160,025 Added 10.96%	1,619,701 $99 Million
Q2 2020 Aug 14, 2020	BUY	$25.95 - $43.15 $1.87 Million - $3.1 Million	71,881 Added 5.18%	1,459,676 $60.7 Million
Q1 2020 May 14, 2020	SELL	$26.15 - $77.24 $26.8 Million - $79.3 Million	-1,026,417 Reduced 42.52%	1,387,795 $39.9 Million
Q4 2019 Feb 18, 2020	BUY	$60.18 - $154.77 $24 Million - $61.7 Million	398,808 Added 19.79%	2,414,212 $174 Million
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $19.9 Million - $27 Million	141,996 Added 7.58%	2,015,404 $283 Million
Q2 2019 Jul 31, 2019	BUY	$157.85 - $183.09 $32.3 Million - $37.5 Million	204,779 Added 12.27%	1,873,408 $343 Million
Q1 2019 Apr 30, 2019	BUY	$89.33 - $163.65 $121 Million - $223 Million	1,359,947 Added 440.57%	1,668,629 $265 Million
Q4 2018 Feb 06, 2019	BUY	$81.94 - $139.71 $3.61 Million - $6.15 Million	44,019 Added 16.63%	308,682 $29.6 Million
Q3 2018 Nov 09, 2018	BUY	$138.11 - $169.04 $12.1 Million - $14.8 Million	87,427 Added 49.33%	264,663 $37.4 Million
Q2 2018 Aug 10, 2018	SELL	$140.36 - $175.76 $1.04 Million - $1.3 Million	-7,413 Reduced 4.01%	177,236 $27.7 Million
Q1 2018 May 14, 2018	SELL	$152.15 - $192.33 $1.88 Million - $2.38 Million	-12,386 Reduced 6.29%	184,649 $29.7 Million
Q4 2017 Feb 09, 2018	BUY	$60.72 - $167.34 $12 Million - $33 Million	197,035	197,035 $32.5 Million

Others Institutions Holding SAGE

# of Institutions

218

Shares Held

46.4M

Call Options Held

847K

Put Options Held

188K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $340M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Sage Therapeutics, Inc. Transaction History